2019 ACC/AHA Guideline on the Primary Prevention of …
2019年3月17日 · For example, robust evidence suggests that both antihypertensive therapy S5-3–S5-6 and statin therapy, S5-7–S5-9 particularly with low-cost generic drug formulations, are high-value interventions across a wide spectrum of risk and age strata.
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the …
2023年7月20日 · LDL-C is a primary cause of atherosclerotic disease and target of lipid management. 38 RCTs established the efficacy and safety of high-intensity statin therapy as the preferred initial approach to reduce LDL-C levels by ≥50% and reduce cardiovascular morbidity and mortality rates . 1–3 Despite maximally tolerated statin therapy, residual ...
Cholesterol Management: ACC/AHA Updates Guideline - AAFP
2019年5月1日 · • Maximally tolerated statin therapy is recommended for patients 20 to 75 years of age with an LDL-C level of 190 mg per dL or greater. • Moderate-intensity statin therapy...
high-intensity statin therapy or maximally tolerated statin therapy. The more LDL-C is -sequent risk reduction. Use a maximally tolerated statin to lower LDL-C levels by ≥50%. 3. In very high-risk ASCVD, use a LDL-C thresh-old of 70 mg/dL (1.8 mmol/L) to consider addition of nonstatins to statin therapy. Very
2019 ACC/AHA Guideline on the Primary Prevention of …
2019年3月7日 · The following are guideline recommendations for statin treatment: Patients ages 20-75 years and LDL-C ≥190 mg/dl, use high-intensity statin without risk assessment. T2DM and age 40-75 years, use moderate-intensity statin and risk estimate to consider high-intensity statins.
Statin Use for the Primary Prevention of Cardiovascular Disease in ...
2022年8月23日 · The USPSTF recommends that clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (i.e. dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year risk of a cardiovascular event of 10% or greater.
Statin Use for the Primary Prevention of Cardiovascular Disease
In patients who have a cardiovascular risk factor and an estimated 10-year CVD risk of 10% or greater, initiate a moderate-intensity statin after discussing the rationale and provided the patient...
A CAC score of 1 to 99 favors statin therapy, especially in those ≥55 years of age. For any patient, if the CAC score is ≥100 Agatston units or ≥75th per-centile, statin therapy is indicated unless otherwise deferred by the outcome of clinician–patient risk discussion. 9 In adults 40 to 75 years of age without diabetes mellitus and
Recommend statins as first-line pharmacotherapy. Consider the combination of statin and nonstatin therapy in selected patients. Discuss potential risk reduction from lipid-lowering therapy. Discuss the potential for adverse effects or drug–drug interactions. Consider cost.
Recommend statins as first-line pharmacotherapy. Consider the combination of statin and nonstatin therapy in selected patients. Discuss potential risk reduction from lipid-lowering therapy. Discuss the potential for adverse effects or drug–drug interactions. Consider cost.